AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|
21.3 C
New York
Tuesday, June 23, 2026

Tag: novel

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SASKATOON, SK, July 29, 2025 /CNW/ - ZYUS Life Sciences...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

BlueSphere Bio CSO Alan Korman Recipient of Esteemed 2025 William B. Coley Award

Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...

Concrete Leprechaun: An Irish-American Coming-of-Age Story Set in the 1970s Bronx

NEW YORK, July 29, 2025 /PRNewswire/ -- Set against the raw, unforgiving backdrop of the 1970s Bronx, Concrete Leprechaun is a coming-of-age tale that cuts...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

BioBond Enters the $9.5B Hot Melt Market With BioBased Technology For Packaging Applications

BioBond Accelerates the Transition to Biobased Hot Melt Adhesives with Better Performance, Better Pricing and Better for Everyone Approach LAFAYETTE, Ind., July 29, 2025 /PRNewswire/...

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial...

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNovel